ACU vs SKYA Stock Comparison

Acme United and SkyAI Prices as of Oct 28, 2026 Peers: Industry group
ACU Acme United Corp
$66.87 +5.1% 1M +73.3% 1Y
Market cap
$256.37M
P/E
24.8x
Revenue (TTM)
—
Div. yield
0.96%
Medical Supplies Healthcare
4 wins
SKYA SkyAI, Inc.
$2.95 +66.7% 1M -42.7% 1Y
Market cap
$212.68M
P/E
–
Revenue (TTM)
$194.22K
Div. yield
–
Medical Supplies Healthcare
1 win

Head to Head

5 decided of 12

Acme United leads on 4 of the 12 questions below (Acme United 4, SkyAI 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionACUSKYALeader
Larger companyMarket capitalisation $256.37M $212.68M ACU
Cheaper on earningsLower P/E, profitable companies only 24.8x -0.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 24.3x 0.0x SKYA
Faster revenue growthRevenue growth, trailing twelve months — +108.9% –
More profitableNet margin, trailing twelve months — -158,431.4% –
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA — — –
Higher dividend yieldTrailing dividend yield 0.96% — –
Better 1-year returnPrice return, last 12 months +73.3% -42.7% ACU
Better 5-year returnAnnualised price return, 5 years +12.6%/yr — –
Less volatileAnnualised volatility, 1 year 30.7% 105.9% ACU
Higher overall scoreMean of the five percentile scores vs peers 71/100 26/100 ACU

Percentile Scorecard

ACUSKYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisACUSKYA
Valuation 88 #28 of 227 2 #222 of 227
Growth – 7 #204 of 219
Profitability – 1 #203 of 205
Financial Health 60 #96 of 237 95 #14 of 237
Shareholder Returns 65 #48 of 135 –
Overall 71 26
  • ACU ranked among 247 companies in Medical Devices and Diagnostics
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodACUSKYASPY
1 month +5.1%+66.7% +0.9%
3 months +12.2%+115.3% +5.9%
6 months +62.7%+68.6% +8.5%
Year to date +65.9%+45.3% +13.3%
1 year +73.3%-42.7% +12.4%
3 years +120.0%-99.9% +88.1%
3 years, per year +30.1%-90.0% +23.5%
5 years +80.7%— +68.2%
5 years, per year +12.6%— +11.0%
10 years +216.9%— +263.4%
10 years, per year +12.2%— +13.8%

Risk

MeasureACUSKYASPY
Volatility, 1Y 30.7%105.9% 12.7%
Downside volatility, 1Y 24.2%104.7% 12.7%
Beta vs S&P 500, 1Y 0.242.60 1.00
Return / volatility, 1Y 2.39-0.40 0.98
Max drawdown, 5Y -43.5%-100.0% -25.4%
From 52-week high 0.0%-42.7% -0.9%
52-week high $66.87$5.15 $779.14
52-week low $35.50$0.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleACUSKYA
P/E now vs peer median 24.8xmedian 28.8x -0.7xmedian 28.8x
P/S now vs peer median 1.2xmedian 3.0x 1,095xmedian 3.0x
EV/EBITDA now vs peer median —median 17.4x —median 17.4x
P/FCF now vs peer median 15.8xmedian 25.7x —median 25.7x
P/B now vs peer median 2.1xmedian 2.4x 1.4xmedian 2.4x
PEG now vs peer median —median 1.03 0.01median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsACUSKYA
Revenue – $194.22K
Gross profit – $321.93K
Operating income – -$289.52M
Net income – -$307.71M
R&D – $399.91K
EPS (diluted) – $-4.27
Cash & equivalents $7.94M $12.07M
Shares (diluted) 4.14M 72.09M
Enterprise value $256.37M $171.38M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricACUSKYA
P/E 24.8x -0.7x
P/FCF 15.8x –
P/Operating cash flow – –
P/S 1.2x 1,095x
P/B 2.1x 1.4x
P/Tangible book 2.8x 16.4x
EV/EBITDA – –
EV/EBIT – -0.7x
EV/Revenue – 1,033x
EV/FCF – –
EV/Operating cash flow – –
PEG (3Y EPS CAGR) – 0.01

Growth

14 metrics
MetricACUSKYA
Revenue growth (1Y) – 108.9%
Revenue CAGR (3Y) – 23.8%
Gross profit growth (1Y) – –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) – -5,525%
Operating income CAGR (3Y) – -212.8%
Net income growth (1Y) – -42,440%
Net income CAGR (3Y) – -238.0%
EPS growth (1Y) – -487.2%
EPS CAGR (3Y) – -84.2%
Operating cash flow growth (1Y) – –
Operating cash flow CAGR (3Y) – –
Free cash flow growth (1Y) – –
Free cash flow CAGR (3Y) – –

Profitability

14 metrics
MetricACUSKYA
Gross margin – 165.8%
EBITDA margin – –
Operating margin – -149,065%
Pretax margin – -151,352%
Net margin – -158,431%
FCF margin – –
Operating cash flow margin – –
Return on equity – -140.2%
Return on assets – -137.6%
Return on invested capital – –
Return on capital employed – -136.7%
Asset turnover – 0.0x
Cash conversion (OCF / net income) – –
Stock comp / revenue – 48,037%

Financial Health

11 metrics
MetricACUSKYA
Debt / assets – –
Debt / equity – –
Net debt / EBITDA – –
Debt / FCF – –
Liabilities / assets 39.9% 1.9%
Equity / assets 60.1% 98.1%
Interest coverage – –
Current ratio 3.9x 5.3x
Quick ratio – 4.4x
Cash ratio – 4.2x
Altman Z-score – 31.97

Shareholder Returns

7 metrics
MetricACUSKYA
Dividend yield 1.0% –
Net buyback yield – –
Shareholder yield 1.0% –
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusACUSKYA
Forward P/E 24.3xFY2026 0.0xFY2026
EPS, next fiscal year $2.75FY2026 $2,362.06FY2026
EPS growth, next FY +10.4%FY2026 –
EPS growth, the year after +4.0% –
Revenue, next fiscal year $217.65MFY2026 $70.01MFY2026
Revenue growth, next FY +10.7%FY2026 +34,200.1%FY2026
Revenue growth, the year after +0.7% +17.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersACUSKYA
Held by institutions 73.5% –
Institutions holding 84 –
Change in shares held, QoQ +1.3% –
Institutions buying 47 –
Institutions selling 21 –
Buyers to sellers 2.24 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ACUSKYA
ACU 1.00 0.00
SKYA 0.00 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ACU and SKYA?

Acme United (ACU) is the largest by market capitalisation: Acme United (ACU) $256.37M, SkyAI (SKYA) $212.68M.

Which stock has performed better?

Over the past year Acme United (ACU) returned the most: Acme United (ACU) +73.3%, SkyAI (SKYA) -42.7%. Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Acme United (ACU) 0.96%. SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Acme United (ACU) has been the steadiest (Acme United (ACU) 30.7%, SkyAI (SKYA) 105.9%). Volatility measures how widely the price swings, not the risk of the business.

Do ACU and SKYA move together?

Their daily returns over the past year have a correlation of -0.00, a negative relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, ACU and SKYA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Acme United (ACU) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.